SB-649868

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020

Retrieved on: 
Wednesday, July 22, 2020
Chemical compounds, Psychoactive drugs, Branches of biology, Hypnotics, Pyridines, Molecular neuroscience, Neuropeptides, Orexin, Lemborexant, Alzheimer's disease, Clinical trial, SB-649868

Regarding BAN2401, the clinical study design of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients will be presented orally.

Key Points: 
  • Regarding BAN2401, the clinical study design of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients will be presented orally.
  • The safety and efficacy results from a Phase II clinical study on lemborexant (orexin receptor antagonist) targeting Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with AD will be presented.
  • Finally, they will hold a discussion on the future outlook of this classification system for Alzheimer's pharmacological trials and clinical practice.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Copyright 2020 JCN Newswire .

New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States

Retrieved on: 
Tuesday, January 15, 2019
Hypnotics, Chemistry, Organic chemistry, Organofluorides, Neurochemistry, RTT, GABAA receptor positive allosteric modulators, Pyrimidines, Lemborexant, Zolpidem, SB-649868

In addition to the treatment of insomnia disorder, a Phase 2 clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia is underway.

Key Points: 
  • In addition to the treatment of insomnia disorder, a Phase 2 clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia is underway.
  • In this study, patients were randomized to receive placebo or one of three treatment regimens (lemborexant 5 mg, lemborexant 10 mg, zolpidem ER 6.25 mg).
  • During the active-only treatment period, patients who received placebo during the first period were re-randomized to receive lemborexant 5 mg or 10 mg.
  • Patients who received active treatment during the first period continued on the treatment to which they were originally randomized.